2024
Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma
Valdez C, Sánchez-Zuno G, Osmani L, Ibrahim W, Galan A, Bacchiocchi A, Halaban R, Kulkarni R, Kang I, Bucala R, Tran T. Prognostic and therapeutic insights into MIF, DDT, and CD74 in melanoma. Oncotarget 2024, 15: 507-520. PMID: 39028303, PMCID: PMC11259151, DOI: 10.18632/oncotarget.28615.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Differentiation, B-LymphocyteBiomarkers, TumorFemaleHistocompatibility Antigens Class IIHumansImmune Checkpoint InhibitorsIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMaleMelanomaMiddle AgedMutationPrognosisRetrospective StudiesSkin NeoplasmsConceptsMacrophage migration inhibitory factorImmune checkpoint inhibitionD-dopachrome tautomeraseExpression of macrophage migration inhibitory factorDrivers of tumor progressionInflammatory cell markersPatient tumor samplesPatient survival outcomesMigration inhibitory factorStatistically significant differenceCheckpoint inhibitionImmune therapyPrognostic valueSurvival outcomesResistant melanomaGene expressionImproved survivalRetrospective studyInflammatory markersTumor progressionCell markersTumor samplesClinical evidenceMelanomaBulk RNA sequencing
2000
Anserine Bursitis in Patients With Osteoarthritis of the Knee
KANG I, HAN S. Anserine Bursitis in Patients With Osteoarthritis of the Knee. Southern Medical Journal 2000, 93: 207-209. PMID: 10701790, DOI: 10.1097/00007611-200002000-00011.Peer-Reviewed Original ResearchAnserine Bursitis in Patients With Osteoarthritis of the Knee
KANG I, HAN S. Anserine Bursitis in Patients With Osteoarthritis of the Knee. Southern Medical Journal 2000, 93: 207-209. DOI: 10.1097/00007611-200093020-00011.Peer-Reviewed Original Research